||The Human IP-10 ELISA is to be used for the quantitative determination in urine.
|Principle of the Method
||The Human IP-10 kit is a solid phase sandwich Enzyme Linked-Immuno-Sorbent Assay (ELISA). A monoclonal antibody specific for IP-10 is has been coated onto the wells of the microtiter strips provided. Samples of Urine supernatant are pipetted into these wells followed by the addition of a second biotinylated monoclonal antibody.During the first incubation, the IP-10 antigen binds to the immobilized (capture) antibody on one site and to the solution phase biotinylated antibody on a second site.After removal of excess second antibody, Streptavidin-Peroxidase (enzyme) is added. This binds to the biotinylated antibody to complete the four-member sandwich. After a second incubation and washing to remove all the unbound enzyme, a substrate solution is added, which is acted upon by the bound enzyme to produce color. The intensity of this colored product is directly proportional to the concentration of IP-10 present in the original specimen.
||Human IP-10, the interferon-gamma inducible protein-10, also known as CXCL10, is a member of CXC chemokine family (1,2). Human IP-10 is produced mainly by monocytes but also T-cells, fibroblasts and endothelial cells (2). Unlike other CXC chemokines, IP-10 is a chemoattractant for activated lymphocytes, but not resting lymphocytes or neutrophils (2).Human IP-10 is a potent inhibitor of angiogenesis; inhibits neovascularization and exerts antitumor effects (3-6). Human IP-10 inhibits proliferation of human endothelial cells (7) and bone marrow derived hematopoietic progenitors (8).The gene for human IP-10 has been mapped to chromosome 4q2 (9). CXC chemokine receptor (CXCR3) has been identified as the receptor for IP-10 (10)
|Ripple Background Information
||Human IP-10 when identified above a certain concentration in urine has experimentally been demonstrated to indicate acute inflammation, tubulitis, and compromised kidney function.